FDA clears IND for Phase 2 study of VT-7208 in CSU
Processa Pharmaceuticals announced FDA clearance for a VT-7208 CSU Phase 2 trial and appointed Dr. Sheila Gujrathi as Executive Chair, supported by a $200M investment.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed